Bispecific ADCs: Targeting Two Tumor Antigens

Bispecific ADCs sit at the intersection of two of oncology’s most active engineering disciplines, combining the dual-targeting precision of bispecific antibodies with the cytotoxic payload delivery of antibody-drug conjugates. As tumors evolve resistance mechanisms and heterogeneous antigen expression challenges single-target therapies, the field is moving toward formats that address multiple vulnerabilities simultaneously.

What is a bispecific ADC, and how does it differ from a conventional ADC?

A bispecific ADC is an antibody-drug conjugate in which the antibody component binds two distinct tumor-associated antigens rather than one, while still carrying a cytotoxic payload for targeted delivery. Conventional ADCs rely on a single antigen for tumor recognition, which creates a single point of failure: if that antigen is downregulated or absent on a subpopulation of tumor cells, those cells escape treatment. By engaging two separate targets, a bispecific ADC increases the probability that the molecule will bind and internalize even when antigen expression is heterogeneous across the tumor.

The structural complexity of bispecific ADCs also introduces a manufacturing challenge that does not exist for monospecific formats. Combining two different heavy chains and two different light chains in a single molecule creates the risk of chain mispairing, where incorrect heavy-light chain combinations assemble during production, generating non-functional or off-target species. Solving this mispairing problem is one of the central engineering priorities for any bispecific ADC program.

Why is tumor antigen heterogeneity a problem that single-target ADCs cannot fully solve?

Tumor antigen heterogeneity means that not all cells within a single tumor express the same surface markers at the same density, and this variation is a primary driver of treatment resistance and relapse. A conventional ADC directed at a single target will eliminate antigen-positive cells efficiently but leave antigen-low or antigen-negative subpopulations intact. Those surviving cells can repopulate the tumor, often with reduced sensitivity to the original therapy.

Bispecific ADCs address this by requiring only one of two antigens to be present for binding and internalization to occur. This broader recognition profile increases tumor coverage and reduces the selective pressure that drives antigen escape. Industry interest in this approach has grown substantially, with bispecific ADCs now ranked among the most frequently discussed complex modalities by oncology drug developers, alongside bispecific T-cell engagers and dual-targeting CAR-T constructs.

How does the chain mispairing problem affect bispecific ADC manufacturing, and what structural solutions exist?

Chain mispairing occurs when the two distinct heavy chains and two distinct light chains of a bispecific antibody assemble incorrectly during cell culture, producing a mixture of intended and unintended molecular species. In a bispecific ADC, this is particularly consequential because mismatched chains can generate molecules that bind the wrong target, fail to internalize, or carry payload to healthy tissue. Purifying the correctly assembled species from this mixture adds cost, reduces yield, and complicates regulatory characterization.

Fully human heavy-chain-only antibodies (HCAbs) eliminate this problem structurally. Because HCAbs contain no light chain, there is no light chain to mispair. Incorporating HCAb-derived single domains as one or both binding arms of a bispecific ADC removes an entire category of manufacturing risk. Nona Biosciences’ HBICE® (HCAb-Based Immune Cell Engager) platform applies this principle directly, using fully human HCAb single-domain binders to build multispecific constructs that are inherently free of light-chain mismatching, which further de-risks manufacturing at scale.

What is the difference between a bispecific ADC and a dual-payload ADC?

These are two distinct engineering strategies for overcoming treatment resistance, and treating them as synonymous leads to confusion in program design. A bispecific ADC uses one payload but two antigen-binding arms, increasing tumor targeting breadth. A dual-payload ADC uses one antigen-binding arm but carries two different cytotoxic payloads with different mechanisms of action.

Both formats are designed to combat resistance, but they do so at different points in the treatment failure cascade. Bispecific ADCs address the problem of antigen loss or downregulation. Dual-payload ADCs address the problem of tumors developing resistance to a specific cell-killing mechanism. Programs targeting highly heterogeneous or treatment-refractory tumors may ultimately require both strategies in combination.

Why are fully human HCAbs particularly well-suited as building blocks for bispecific ADCs?

Fully human HCAbs from Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies) offer three structural properties that make them especially valuable in bispecific ADC construction. First, their small size, approximately half the molecular weight of a conventional IgG, improves tumor penetration, which is critical for solid tumors with dense extracellular matrices. Second, the absence of a light chain eliminates mispairing during bispecific assembly. Third, because they are fully human in sequence, they carry no residual non-human residues, unlike humanized antibodies derived from camelid.

This last point matters for ADC programs specifically. Humanized antibodies, produced by grafting non-human complementarity-determining regions onto a human framework, retain residual non-human sequences that can trigger immunogenic responses in patients. Fully human HCAbs, generated through natural in vivo immune selection in Harbour Mice®, are inherently compatible with human immune tolerance. For an ADC program advancing toward clinical development, this distinction reduces immunogenicity risk without requiring additional humanization engineering steps. Nona Biosciences’ fully human antibody discovery platform is built around this capability.

How does the tumor microenvironment factor into next-generation bispecific ADC design?

Conditional activation within the tumor microenvironment (TME) is an active design strategy for reducing off-target toxicity in ADC programs. Rather than releasing cytotoxic payload systemically, next-generation ADCs are being engineered to become active only under TME-specific conditions, such as low pH, elevated protease activity, or hypoxia. This approach spares healthy tissue while concentrating cytotoxic activity at the tumor site.

Bispecific ADCs can layer TME-conditional activation on top of dual-target recognition, creating a two-stage selectivity filter: the molecule must bind at least one of two tumor antigens and must encounter TME conditions before releasing payload. This combination is among the most sophisticated approaches currently in development and reflects the broader industry shift toward reducing both off-target and on-target/off-disease toxicity. Developers working on bispecific and multispecific engineering programs are increasingly incorporating TME-responsive linker chemistry as a standard design consideration.

When should a drug developer choose a bispecific ADC format over a monospecific ADC?

A bispecific ADC format is most appropriate when the target tumor is known to express heterogeneous antigen profiles, when prior monospecific ADC programs have failed due to antigen escape, or when two tumor-associated antigens are co-expressed in a pattern that can be exploited for synergistic internalization. Monospecific ADCs remain the simpler and faster path when a single high-density, uniformly expressed antigen is available and resistance is not a primary concern.

The decision also depends on manufacturing readiness. Bispecific ADC programs require antibody engineering expertise, chain mispairing mitigation strategies, and developability assessment across a more complex molecular format. Partnering with Nona offers access to HCAbs from Harbour Mice® as structurally clean building blocks, combined with Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) to guide sequence selection and reduce attrition before conjugation chemistry is introduced. For programs where the biology supports dual targeting, this integrated approach shortens the path from concept to a developable lead.

What does Nona Biosciences’ track record indicate about its readiness to support bispecific ADC programs?

Nona Biosciences has completed more than 300 antibody discovery programs and has 19 or more clinical-stage molecules derived from its platforms, providing a validated foundation for complex modality programs including bispecific ADCs. The AstraZeneca strategic collaboration and the Pfizer MesoC2 ADC program, presented at ASCO in Phase 1, demonstrate that Nona’s discovery and engineering capabilities translate into clinical-stage assets across multiple partner organizations.

For bispecific ADC programs specifically, Nona’s Idea toward IND (I-to-I®) (Nona’s integrated end-to-end service pathway from ideation through IND filing) provides a structured route from target identification through preclinical package completion. This pathway integrates antigen preparation, HCAb discovery via Harbour Mice®, single B-cell screening using Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation), bispecific engineering, developability assessment, and pharmacological evaluation under one coordinated program. Developers who need both the antibody engineering expertise and the downstream preclinical infrastructure can access both through a single partnership rather than managing multiple vendors across the discovery-to-IND continuum.

What are the key developability considerations specific to bispecific ADCs that developers should address early?

Bispecific ADCs face a compounded set of developability risks compared to either monospecific ADCs or unconjugated bispecifics. The antibody component must be stable under conjugation conditions, maintain binding to both antigens after payload attachment, and support the drug-to-antibody ratio (DAR) required for therapeutic efficacy without aggregating. These requirements must be assessed simultaneously rather than sequentially.

Early-stage developability screening should evaluate thermal stability, aggregation propensity, and binding retention for both arms after conjugation. Nona’s Hu-mAtrIx™ AI platform integrates developability-optimized sequence guidance directly into the lead selection process, reducing the probability that a lead antibody will fail at the conjugation or formulation stage. Addressing these parameters before committing to a lead candidate is substantially more efficient than attempting to rescue a poorly developable molecule after conjugation chemistry has been established. Nona’s bispecific antibody developability assessment service is designed specifically to surface these risks at the earliest actionable stage.

Developers building bispecific ADC programs face a convergence of structural, manufacturing, and clinical challenges that require integrated expertise across antibody engineering, conjugation chemistry, and preclinical evaluation. Working with Nona provides access to fully human HCAbs from Harbour Mice®, AI-guided lead optimization through Hu-mAtrIx™, and a complete Idea toward IND (I-to-I®) pathway, all structured to move complex modalities from concept to clinical candidate with reduced attrition. To discuss how Nona’s platforms can support your bispecific ADC program, connect with Nona’s discovery team.

1. Shastry M. et al., Antibody-drug conjugates in breast cancer: current status and future directions, NPJ Breast Cancer, 2023. Link

2. Goebeler M.E. et al., Bispecific antibodies for cancer therapy: a review, Pharmacology and Therapeutics, 2020. Link

3. Tarantino P. et al., Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies, CA: A Cancer Journal for Clinicians, 2022. Link

4. Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link

5. Strop P. et al., Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates, Chemistry and Biology, 2013. Link

6. Mack F. et al., Bispecific antibodies for cancer immunotherapy, Current Opinion in Oncology, 2016. Link

7. Deonarain M.P. et al., Small-format drug conjugates: a viable alternative to ADCs for solid tumours?, Antibodies, 2018. Link

8. Schmitt M.W. et al., Tumor heterogeneity and cancer evolution, Nature Reviews Genetics, 2016. Link